Abstract
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder representing the most common form of dementia and the most feared highly disabling age-related condition of our time. Hallmarks of AD include a dramatically increasing number of cases due to prospected demographics and the absence of a cure. AD is incurable as it escapes the formula “one disease, one mechanism, one drug”. AD has a multifaceted pathophysiology only in part uncovered. Even the proven chronological primacy of free radical-related damage in AD-related neurodegeneration has not yield successful oxidative stress – lowering trial designs. As a consequence, clinical trials of antioxidants in AD have brought largely negative conclusions. The aims of this review are to discuss 1. rationale for antioxidant trials, 2. reasons for failure of antioxidants in AD therapy, 3. potential preventive benefits of natural nutrition against AD onset and 4. the enormous relevance of detecting and treating AD risk factors as long as possible prior to AD manifestation.
Keywords: Clinical trial, antioxidant, oxidative stress, free radical, Alzheimer's disease, mild cognitive impairment.
Current Pharmaceutical Design
Title:Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives
Volume: 20 Issue: 18
Author(s): Maria Cristina Polidori and Gereon Nelles
Affiliation:
Keywords: Clinical trial, antioxidant, oxidative stress, free radical, Alzheimer's disease, mild cognitive impairment.
Abstract: Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder representing the most common form of dementia and the most feared highly disabling age-related condition of our time. Hallmarks of AD include a dramatically increasing number of cases due to prospected demographics and the absence of a cure. AD is incurable as it escapes the formula “one disease, one mechanism, one drug”. AD has a multifaceted pathophysiology only in part uncovered. Even the proven chronological primacy of free radical-related damage in AD-related neurodegeneration has not yield successful oxidative stress – lowering trial designs. As a consequence, clinical trials of antioxidants in AD have brought largely negative conclusions. The aims of this review are to discuss 1. rationale for antioxidant trials, 2. reasons for failure of antioxidants in AD therapy, 3. potential preventive benefits of natural nutrition against AD onset and 4. the enormous relevance of detecting and treating AD risk factors as long as possible prior to AD manifestation.
Export Options
About this article
Cite this article as:
Polidori Cristina Maria and Nelles Gereon, Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives, Current Pharmaceutical Design 2014; 20 (18) . https://dx.doi.org/10.2174/13816128113196660706
DOI https://dx.doi.org/10.2174/13816128113196660706 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation and Function of Rankl in Arterial Calcification
Current Pharmaceutical Design Effect of Kegel Exercises on Pelvic Floor Muscle Disorders in Prenatal and Postnatal Women - A Literature Review
Current Women`s Health Reviews Molecular Mechanisms of Restenosis After Percutaneous Peripheral Angioplasty and Approach to Endovascular Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Dendritic Cell Endothelium Interaction in Autoimmunity
Current Pharmaceutical Design Delivery of Large Genomic DNA Inserts > 100 kb Using HSV-1 Amplicons
Current Gene Therapy Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures
Current Medicinal Chemistry Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Developments in Antithrombotic Therapy: Will Sodium Warfarin Be a Drug of the Past?
Recent Patents on Cardiovascular Drug Discovery Marine Collagen as a Source of Bioactive Molecules: A Review
The Natural Products Journal The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents
Medicinal Chemistry Tissue-Specific Targeting for Cardiovascular Gene Transfer. Potential Vectors and Future Challenges
Current Gene Therapy Novel Agents to Manage Dyslipidemias and Impact Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Molecular Mechanisms of Glucocorticoids Action: From Basic Research to Clinical Implications
Current Immunology Reviews (Discontinued) Molecular Markers of Cardiovascular Damage in Hypertension
Current Pharmaceutical Design